NLR、VEGF、IL-6、TNF-α水平与非小细胞肺癌预后的相关性
|
摘要
目的:研究中性粒细胞/淋巴细胞比例(NLR)、血管内皮生长因子(vascular endothelial growth factor,VEGF)、白介素-6(interleukin-6,IL-6)、肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)水平与非小细胞肺癌预后的相关性。方法:选取2016年2月至2018年2月在我院确诊并进行手术治疗的非小细胞肺癌患者50例,取所有患者手术切除癌组织标本以及与癌组织距离5 cm以上的癌旁组织制作标本,之后进行免疫组化标记以及革兰染色,进行NLR水平检测,酶联免疫吸附法检测IL-6、TNF-α水平,双抗体夹心法检测VEGF水平。结果:癌组织中NLR、VEGF、IL-6、TNF-α水平显著高于癌旁组织中NLR、VEGF、IL-6、TNF-α水平,具有统计学差异(P<0.05)。非小细胞肺癌患者术前NLR、VEGF、IL-6、TNF-α水平与性别、年龄无关,与病理分期、淋巴结转移情况、肿瘤体积以及分化程度有关,Ⅲ期、有淋巴结转移、肿瘤体积较大以及分化程度较低的患者NLR、VEGF、IL-6、TNF-α水平较高,差异具有统计学意义(P <0. 05)。术前NLR、VEGF、IL-6、TNF-α水平与非小细胞肺癌预后呈正相关,具有统计学差异(P <0. 05)。结论:NLR、VEGF、IL-6、TNF-α在非小细胞肺癌中均呈异常表达,与非小细胞肺癌患者的预后密切相关。
Objective:To study the correlation between the ratio of neutrophil to lymphocyte(NLR),vascular endothelial growth factor(VEGF),interleukin-6(IL-6),tumor necrosis factor-α(TNF-α) and the prognosis of NSCLC.Methods:Fifty patients with non-small cell lung cancer(NSCLC) who were diagnosed and treated surgically in our hospital from February 2016 to February 2018 were selected.All the resected cancer tissues and normal tissues adjacent to the cancer tissues more than 5 cm were taken as samples.Immunohistochemical staining and Gram staining were used to detect the level of NLR and ELISA.The levels of IL-6 and TNF-α were detected by adsorption,and VEGF level was detected by double antibody sandwich method.Results:The levels of NLR,VEGF,IL-6 and TNF-α in cancer tissues were significantly higher than those in adjacent tissues(P<0.05).The levels of NLR,VEGF,IL-6 and TNF-α in patients with non-small cell lung cancer before operation were not related to gender and age,but to pathological stage,lymph node metastasis,tumor volume and differentiation degree.The levels of NLR,VEGF,IL-6 and TNF-α were higher in patients with Ⅲ stage,lymph node metastasis,larger tumor volume and lower differentiation degree.There was statistical significance(P<0.05).The levels of NLR,VEGF,IL-6 and TNF-α were positively correlated with the prognosis of NSCLC(P<0.05).Conclusion:NLR,VEGF,IL-6 and TNF-α are all abnormally expressed in NSCLC and are closely related to the prognosis of NSCLC patients.
Objective:To study the correlation between the ratio of neutrophil to lymphocyte(NLR),vascular endothelial growth factor(VEGF),interleukin-6(IL-6),tumor necrosis factor-α(TNF-α) and the prognosis of NSCLC.Methods:Fifty patients with non-small cell lung cancer(NSCLC) who were diagnosed and treated surgically in our hospital from February 2016 to February 2018 were selected.All the resected cancer tissues and normal tissues adjacent to the cancer tissues more than 5 cm were taken as samples.Immunohistochemical staining and Gram staining were used to detect the level of NLR and ELISA.The levels of IL-6 and TNF-α were detected by adsorption,and VEGF level was detected by double antibody sandwich method.Results:The levels of NLR,VEGF,IL-6 and TNF-α in cancer tissues were significantly higher than those in adjacent tissues(P<0.05).The levels of NLR,VEGF,IL-6 and TNF-α in patients with non-small cell lung cancer before operation were not related to gender and age,but to pathological stage,lymph node metastasis,tumor volume and differentiation degree.The levels of NLR,VEGF,IL-6 and TNF-α were higher in patients with Ⅲ stage,lymph node metastasis,larger tumor volume and lower differentiation degree.There was statistical significance(P<0.05).The levels of NLR,VEGF,IL-6 and TNF-α were positively correlated with the prognosis of NSCLC(P<0.05).Conclusion:NLR,VEGF,IL-6 and TNF-α are all abnormally expressed in NSCLC and are closely related to the prognosis of NSCLC patients.
引文
[1] Liu B,Zhou XJ.Expert consensus on immunohistochemical markers of non-small cell lung cancer(2014) [J].Journal of Clinical and Experimental Pathology,2015,31(5):481-487.[刘标,周晓军.非小细胞肺癌免疫组化标志物专家共识(2014)[J].临床与实验病理学杂志,2015,31(5):481-487.]
[2] Suresh K,Naidoo J,Lin CT,et al.Immune checkpoint immunotherapy for non-small cell lung cancer:Benefits and pulmonary toxicities[J].Chest,2018,4:32336.
[3] Song Y.Value of vascular endothelial growth factor combined with tumor markers in the diagnosis of non-small cell lung cancer[J].Systemic Medicine,2017,2(23):103-105.[宋颖.血管内皮生长因子联合肿瘤标记物检测在非小细胞肺癌诊断中的应用价值[J].系统医学,2017,2(23):103-105.]
[4] Geng J,Li X,Zhou Z,et al.EZH2 promotes tumor progression via regulating VEGF-A/AKT signaling in non-small cell lung cancer[J].Cancer Lett,2015,359(2):275-287.
[5] Wang S,Yan Y,Cheng Z,et al.Sotetsuflavone suppresses invasion and metastasis in non-small-cell lung cancer A549 cells by reversing EMT via the TNF-α/NF-κB and PI3K/AKT signaling pathway[J].Cell Death Discov,2018,4(4):26.
[6] Hung YP,Sholl LM.Diagnostic and predictive immunohistochemistry for non-small cell lung carcinomas[J].Adv Anat Pathol,2018,25(6):374-386.
[7] Zhang Yanfang,Niu Chunlian,Li Jiangli,et al.The effect of preoperative neutrophil/lymphocyte ratio and Glasgow score on the prognosis of non-small cell lung cancer[J].Modern Oncology,2016,24(8):1221-1223.[张艳芳,牛春莲,李江丽,等.术前中性粒细胞/淋巴细胞比值和Glasgow评分对非小细胞肺癌预后的影响[J].现代肿瘤医学,2016,24(8):1221-1223.]
[8] Liu J,Sun W.IL - 6 in non-small cell lung cancer tissue and IGF - 1 the expression and clinical significance of [J].Chinese Journal of Histochemistry and Cytochemistry,2015,24 (5):399-403.
[9] Wu YJ,Zhao DH.T lymphocyte subsets,neutral lymphocyte ratio and clinical stage of non-small cell lung cancer[J].Journal of Anhui Medical University,2017,52(6):912-914.[吴玉洁,赵大海.T细胞亚群、中性淋巴比值与肺癌病理分型及非小细胞肺癌临床分期的相关性分析[J].安徽医科大学学报,2017,52(6):912-914.]
[10] Fang SC,Zhang YM,Zhang ML,et al.The value of neutrophil-to-lymphocyte ratio in evaluating the prognosis of patients with advanced non-small cell lung cancer [J].Journal of Clinical Pulmonary Medicine,2018,23(7):1202-1204,1209.[方申存,张映铭,张梅玲,等.中性粒细胞与淋巴细胞比率在评估晚期非小细胞肺癌患者预后的价值[J].临床肺科杂志,2018,23(7):1202-1204,1209.]
[11] Sou HJ,Wang CL.Clinical significance of preoperative neutrophil lymphocyte ratio test in evaluating the prognosis of patients with radical resection of non-small cell lung cancer[J].Chinese Journal of Geriatrics,2016,36(21):5352-5355.[索海进,王长利.术前中性粒细胞淋巴细胞比率检测评估行根治性切除的非小细胞肺癌患者预后的临床意义[J].中国老年学杂志,2016,36(21):5352-5355.]
[12] Cao WR,Yan WX,Wang XL,et al.Expression and significance of VEGF and Bax in non-small cell lung cancer tissues[J].Chongqing Medical Science,2016,45(3):307-309.
[13] Pan J,Bi Y,Ren YX,et al.Value of combined detection of serum cytokeratin 19 fragment,tumor-associated sugar chain antigen and vascular endothelial growth factor in the diagnosis of non-small cell lung cancer[J].Journal of Modern Chinese and Western Medicine,2015,24(12):1340-1341,1346.[潘洁,毕怡,任玉欣,等.血清细胞角蛋白19片段、肿瘤相关糖链抗原、血管内皮生长因子联合检测诊断非小细胞肺癌的价值[J].现代中西医结合杂志,2015,24(12):1340-1341,1346.]
[14] Xu KQ.Value of vascular endothelial growth factor combined with tumor markers in the diagnosis of non-small cell lung cancer[J].Journal of Applied Cancer,2017,32(3):389-391.
[15] Dai Chun,Zhou Yongchun,Huang Yunchao,et al.The relationship between serum levels of cytokines (IL-2,IL-4,IL-6,IL-10) and clinical stages in patients with non-small cell lung cancer [J].Modern Oncology,2015,23(6):779-781.[戴春,周永春,黄云超,等.非小细胞肺癌患者血清中细胞因子(IL-2、IL-4、IL-6、IL-10)的含量与临床分期的关系[J].现代肿瘤医学,2015,23(6):779-781.]
[16] Sun Z,Xue Y,Wang DX,et al.Correlation between serum HGF and IL-6 levels and prognosis of non-small cell lung cancer [J].Journal of Local Surgery,2015,24(4):403-405.[孙真,薛颖,王东霞,等.血清HGF和IL-6水平与非小细胞肺癌预后的相关性研究[J].局解手术学杂志,2015,24(4):403-405.]
[17] Kumar S,Guleria R,Singh V,et al.Lack of utility of plasma TNF-alpha level in predicting therapeutic efficacy in patients with advanced non-small cell lung cancer[J].Cytokine,2010,51(3):245-248.
[18] Jia Y,Li X,Zhao C,et al.Impact of serum vascular endothelial growth factor and interleukin-6 on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small-cell lung cancer[J].Lung Cancer,2018(125):22-28.
[19] Guo LS.Taxol in non-small cell lung cancer patients serum TNF alpha and MMPs [J].Journal of Clinical Medicine,2016,20(3):137-139.[郭良苏.紫杉醇对非小细胞肺癌患者血清TNF-α和MMPs的影响[J].实用临床医药杂志,2016,20(3):137-139.]
[20] Zhang XX,Liang BX,Zhang WZ,et al.Effect of sodium cantharidinate vitamin B6 on serum tumor necrosis factor-alpha and interleukin-12 in patients with non-small cell lung cancer[J].Chinese Journal of Physicians,2015,17(1):48-51.[张晓笑,梁斌鑫,张婉珠,等.斑蝥酸钠维生素B6对非小细胞肺癌患者血清肿瘤坏死因子-α和白介素-12的影响[J].中国医师杂志,2015,17(1):48-51.]
[2] Suresh K,Naidoo J,Lin CT,et al.Immune checkpoint immunotherapy for non-small cell lung cancer:Benefits and pulmonary toxicities[J].Chest,2018,4:32336.
[3] Song Y.Value of vascular endothelial growth factor combined with tumor markers in the diagnosis of non-small cell lung cancer[J].Systemic Medicine,2017,2(23):103-105.[宋颖.血管内皮生长因子联合肿瘤标记物检测在非小细胞肺癌诊断中的应用价值[J].系统医学,2017,2(23):103-105.]
[4] Geng J,Li X,Zhou Z,et al.EZH2 promotes tumor progression via regulating VEGF-A/AKT signaling in non-small cell lung cancer[J].Cancer Lett,2015,359(2):275-287.
[5] Wang S,Yan Y,Cheng Z,et al.Sotetsuflavone suppresses invasion and metastasis in non-small-cell lung cancer A549 cells by reversing EMT via the TNF-α/NF-κB and PI3K/AKT signaling pathway[J].Cell Death Discov,2018,4(4):26.
[6] Hung YP,Sholl LM.Diagnostic and predictive immunohistochemistry for non-small cell lung carcinomas[J].Adv Anat Pathol,2018,25(6):374-386.
[7] Zhang Yanfang,Niu Chunlian,Li Jiangli,et al.The effect of preoperative neutrophil/lymphocyte ratio and Glasgow score on the prognosis of non-small cell lung cancer[J].Modern Oncology,2016,24(8):1221-1223.[张艳芳,牛春莲,李江丽,等.术前中性粒细胞/淋巴细胞比值和Glasgow评分对非小细胞肺癌预后的影响[J].现代肿瘤医学,2016,24(8):1221-1223.]
[8] Liu J,Sun W.IL - 6 in non-small cell lung cancer tissue and IGF - 1 the expression and clinical significance of [J].Chinese Journal of Histochemistry and Cytochemistry,2015,24 (5):399-403.
[9] Wu YJ,Zhao DH.T lymphocyte subsets,neutral lymphocyte ratio and clinical stage of non-small cell lung cancer[J].Journal of Anhui Medical University,2017,52(6):912-914.[吴玉洁,赵大海.T细胞亚群、中性淋巴比值与肺癌病理分型及非小细胞肺癌临床分期的相关性分析[J].安徽医科大学学报,2017,52(6):912-914.]
[10] Fang SC,Zhang YM,Zhang ML,et al.The value of neutrophil-to-lymphocyte ratio in evaluating the prognosis of patients with advanced non-small cell lung cancer [J].Journal of Clinical Pulmonary Medicine,2018,23(7):1202-1204,1209.[方申存,张映铭,张梅玲,等.中性粒细胞与淋巴细胞比率在评估晚期非小细胞肺癌患者预后的价值[J].临床肺科杂志,2018,23(7):1202-1204,1209.]
[11] Sou HJ,Wang CL.Clinical significance of preoperative neutrophil lymphocyte ratio test in evaluating the prognosis of patients with radical resection of non-small cell lung cancer[J].Chinese Journal of Geriatrics,2016,36(21):5352-5355.[索海进,王长利.术前中性粒细胞淋巴细胞比率检测评估行根治性切除的非小细胞肺癌患者预后的临床意义[J].中国老年学杂志,2016,36(21):5352-5355.]
[12] Cao WR,Yan WX,Wang XL,et al.Expression and significance of VEGF and Bax in non-small cell lung cancer tissues[J].Chongqing Medical Science,2016,45(3):307-309.
[13] Pan J,Bi Y,Ren YX,et al.Value of combined detection of serum cytokeratin 19 fragment,tumor-associated sugar chain antigen and vascular endothelial growth factor in the diagnosis of non-small cell lung cancer[J].Journal of Modern Chinese and Western Medicine,2015,24(12):1340-1341,1346.[潘洁,毕怡,任玉欣,等.血清细胞角蛋白19片段、肿瘤相关糖链抗原、血管内皮生长因子联合检测诊断非小细胞肺癌的价值[J].现代中西医结合杂志,2015,24(12):1340-1341,1346.]
[14] Xu KQ.Value of vascular endothelial growth factor combined with tumor markers in the diagnosis of non-small cell lung cancer[J].Journal of Applied Cancer,2017,32(3):389-391.
[15] Dai Chun,Zhou Yongchun,Huang Yunchao,et al.The relationship between serum levels of cytokines (IL-2,IL-4,IL-6,IL-10) and clinical stages in patients with non-small cell lung cancer [J].Modern Oncology,2015,23(6):779-781.[戴春,周永春,黄云超,等.非小细胞肺癌患者血清中细胞因子(IL-2、IL-4、IL-6、IL-10)的含量与临床分期的关系[J].现代肿瘤医学,2015,23(6):779-781.]
[16] Sun Z,Xue Y,Wang DX,et al.Correlation between serum HGF and IL-6 levels and prognosis of non-small cell lung cancer [J].Journal of Local Surgery,2015,24(4):403-405.[孙真,薛颖,王东霞,等.血清HGF和IL-6水平与非小细胞肺癌预后的相关性研究[J].局解手术学杂志,2015,24(4):403-405.]
[17] Kumar S,Guleria R,Singh V,et al.Lack of utility of plasma TNF-alpha level in predicting therapeutic efficacy in patients with advanced non-small cell lung cancer[J].Cytokine,2010,51(3):245-248.
[18] Jia Y,Li X,Zhao C,et al.Impact of serum vascular endothelial growth factor and interleukin-6 on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small-cell lung cancer[J].Lung Cancer,2018(125):22-28.
[19] Guo LS.Taxol in non-small cell lung cancer patients serum TNF alpha and MMPs [J].Journal of Clinical Medicine,2016,20(3):137-139.[郭良苏.紫杉醇对非小细胞肺癌患者血清TNF-α和MMPs的影响[J].实用临床医药杂志,2016,20(3):137-139.]
[20] Zhang XX,Liang BX,Zhang WZ,et al.Effect of sodium cantharidinate vitamin B6 on serum tumor necrosis factor-alpha and interleukin-12 in patients with non-small cell lung cancer[J].Chinese Journal of Physicians,2015,17(1):48-51.[张晓笑,梁斌鑫,张婉珠,等.斑蝥酸钠维生素B6对非小细胞肺癌患者血清肿瘤坏死因子-α和白介素-12的影响[J].中国医师杂志,2015,17(1):48-51.]